In EGFR-mutant advanced NSCLC patients a common approach for treating oligoprogression is to continue the EGFR-TKI (that is controlling the greater proportion of the disease), while using local ablative therapy to eradicate the resistant clones in the area or areas of radiological progression. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.